CytomX Therapeutics, Inc. (CTMX) Fair Value 2026

CTMX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-08-28, CytomX Therapeutics, Inc. (CTMX) trades at $3.21. QOC: 6.3/10. Value Trap Risk: 39/100 (LOW). 1/13 models active.

Key Facts

Ticker
CTMX
Price
$3.21
Quality Score
6.3/10
Value Trap Risk
39/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give CTMX?

1 Intrinsic Value Models vs. Current Price ($3.21)

Core Models (Unlocked)
Model Fair Value Upside
Scenario · High Conviction
 $0.32 -90.2%

All Models Active

All 1 models are displayed above.

What Is CytomX Therapeutics, Inc. (CTMX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, CytomX Therapeutics, Inc.'s intrinsic value is estimated at $0.32. Trading at its current price of $3.21, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -90.2%.

What Do the Models Say About CTMX?

1 of 13 models are currently active for CTMX. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does CTMX Rank in Biotechnology?

Among 625 Biotechnology stocks, CTMX ranks #109 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

CytomX Therapeutics, Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including first-mover advantage in novel targets — shape both the opportunity set and risk profile.

Is CTMX a Value Trap?

CirclFi's Value Trap algorithm assigns CTMX a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for CytomX Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, CytomX Therapeutics, Inc. earns a quality score of 6.3/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CTMX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CTMX's 1 active models, average confidence is 54%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy CytomX Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

STROSutro Biopharma, Inc.QOC 6.3ASMBAssembly Biosciences, Inc.QOC 6.3TCRXTScan Therapeutics, Inc.QOC 6.4QUREuniQure N.V.QOC 6.3IONSIonis Pharmaceuticals, Inc.QOC 6.4VTGNVistagen Therapeutics, Inc.QOC 6.3DAREDaré Bioscience, Inc.QOC 5.2AVTXAvalo Therapeutics, Inc.QOC 4.6XCURExicure, Inc.QOC 3.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: STRO · ASMB · TCRX · QURE · IONS · VTGN · DARE · AVTX · XCUR · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CTMX?

5 companies across all industries closest to CTMX’s Quality of Company score of 6.3/10.

VPRBVPR Brands, LPQOC 6.3PETVPetVivo Holdings, Inc.QOC 6.3SFLSFL Corporation Ltd.QOC 6.3CREXCreative Realities, Inc.QOC 6.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: VPRB · PETV · SFL · CREX · NVDA

Where Does CTMX Sit in CirclFi's Biotechnology Rankings?

CTMX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About CytomX Therapeutics, Inc.’s Valuation?

What is CytomX Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for CytomX Therapeutics, Inc. (CTMX). The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CTMX overvalued or undervalued right now?

At $3.21, 0 of 1 active models suggest CTMX may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits CytomX Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.3 mean for CTMX?

CytomX Therapeutics, Inc.'s QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CTMX?

CirclFi analyzes CTMX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CTMX a value trap in 2026?

CytomX Therapeutics, Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns CytomX Therapeutics, Inc. (CTMX) a Quality of Company score of 6.3/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CTMX/ · Methodology
Primary sources for this CTMX valuation
  • Financial statements: CytomX Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001501989) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CTMX as of ; valuations recomputed .